Vitamin D Supplementation and Metabolism in Vitamin D Deficient Elderly (VitD)

Effects of Vitamin D Supplementation With and With Out Exercise on Metabolic and Physical Consequences of Vitamin D Deficiency in the Elderly

The purpose of this study is to examine the effects of Vitamin D supplementation on the reasons (mechanisms) underlying the development of type 2 diabetes, metabolic syndrome (high blood pressure, cholesterol, diabetes, body weight/obesity), muscle weakness and wasting (sarcopenia), and impaired physical function (poor balance and walking) associated with vitamin D deficiency and osteopenia/osteoporosis (bone loss). The investigators obtain vitamin D through our diet and sunlight, and its conversion to active vitamins in the liver and kidneys promotes the intestinal absorption of calcium and regulation of bone growth. Therefore, vitamin D deficiency has been known for years to lead to weakened bones (osteopenia and osteoporosis). However, more recently, studies show vitamin D deficiency is associated with a number of other diseases, including type 2 diabetes, muscle weakness, frailty, and the metabolic syndrome. It has also been associated with cognitive impairment. Diabetes affects multiple organ systems including the heart, kidneys, musculoskeletal and nervous system. The possibility that vitamin D deficiency is linked to the development of type 2 diabetes, metabolic syndrome, muscle weakness and wasting (sarcopenia) and osteopenia/osteoporosis, and that vitamin D supplementation decreases the risk for these diseases, provides a relatively easy/accessible and inexpensive model of preventive therapy to decrease the incidence of these diseases. In addition, it is likely that genetic (inherited) factors play a role, but the relationship of these genes to these metabolic abnormalities have not been elucidated. Understanding the role of Vitamin D in health will allow us to translate these findings into therapy.

Study Overview

• Status: Terminated
• Conditions: Metabolic Syndrome; Vitamin D Deficiency
• Intervention / Treatment: Dietary supplement: RDA Vitamin D3 only; Dietary supplement: Vitamin D2/3 Repletion only; Other: Vitamin D2/3 Repletion + AEX; Other: Vitamin D2/3 Repletion + RT

• Study Type: Interventional
• Enrollment (Actual): 39
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • Baltimore VAMC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• 40-85 years of age
• Women must be post menopausal (absence of menses for 12 months or greater)
• 25-hydroxyvitamin D level below 20 ng/ml (50 nmol/L)
• BMI 25-45 kg/m2
• Non smoker ( non smoking for at least 12 months:cigarettes, cigars, pipes)

Exclusion Criteria:

• Symptomatic heart disease, CAD, CHF, or uncontrolled hypertension (BP over 180 mm HG) unless medically stabilized
• Currently being treated for active cancer
• Type 1 diabetes; insulin treatment for diabetes, poorly controlled diabetes, HgA1c >10%
• Allergic to lidocaine
• History of seizures or taking anti-seizure or anti convulsion medications
• Untreated dyslipidemia with National Cholesterol ATPIII 10 year cardiac risk score greater than 10% (www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04.htm)
• Taking oral steroids, warfarin or other medications interfering with fat/muscle metabolism that may not be safely discontinued temporarily for specific procedures (ie for 72 hours prior)
• Taking medication that interfere with ability to replete Vitamin D
• Abnormal liver function 2 times normal levels
• Abnormal renal function (BUN above 40 mg/dl, Cr above 1.8 mg/dl, CrCl<60mg/dl)
• Hypercalcemia (Ca>10.2mg/dl)
• Anemia HCT below 30 mg/dl, platelets below 100,000/cm3
• Chronic pulmonary disease (on supplemental O2)
• Other systemic disorders that are not medically treated and stable or affect the ability to absorb Vitamin D.
• MMSE below 24, dementia or unstable clinical depression by exam
• Abnormal response to exercise test (ST segment depression greater than 2mm, chest pain, significant arrhythmias, extreme shortness of breath, cyanosis, exercising BP above 240/120 mm HG, or other contraindications to exercise) *requires follow up treatment w/ primary MD for continued participation in study
• Aerobically trained with VO2max greater than 2 SD above age-adjusted mean
• Participant is, in the opinion of the investigator, unable to adhere to the study protocol due to medical or orthopedic conditions that limit ability to exercise or travel to the Baltimore VA for protocol procedures.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Factorial Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: RDA Vitamin D	Dietary supplement: RDA Vitamin D3 only; 800 IU of Vitamin D3 daily for 6 months; Other Names: ergocalciferol
Experimental: Vit D repletion + 6M Supplementation	Dietary supplement: Vitamin D2/3 Repletion only; Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily; Other Names: cholecalciferol; ergocalciferol
Experimental: Vit D repletion + 6M Supplementation +AEX	Other: Vitamin D2/3 Repletion + AEX; Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus aerobic exercise training; Other Names: cholecalciferol; ergocalciferol
Experimental: Vit D repletion + 6M Supplementation +RT	Other: Vitamin D2/3 Repletion + RT; Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus resistance training; Other Names: cholecalciferol; ergocalciferol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
glucose tolerance and insulin sensitivity	Baseline, 3 months and 6 months

Secondary Outcome Measures

Outcome Measure	Time Frame
muscle structure, inflammation and metabolic function to cause sarcopenia and frailty	Baseline, 3 months and 6 months
physical performance, balance and strength to increase strength and balance to reduce fall risk in older people	Baseline, 3 months and 6 months
cognitive function	Baseline, 3 months and 6 months

Collaborators and Investigators

• Sponsor: Baltimore VA Medical Center
• Collaborators: National Institute on Aging (NIA); Nutrition Obesity Research Center (NORC)
• Investigators: Principal Investigator: Andrew P Goldberg, M.D., Baltimore VAMC/GRECC

Study record dates

Study Major Dates

• Study Start: May 1, 2010
• Primary Completion (Actual): February 1, 2013
• Study Completion (Actual): February 1, 2013

Study Registration Dates

• First Submitted: June 16, 2010
• First Submitted That Met QC Criteria: June 16, 2010
• First Posted (Estimate): June 17, 2010

Study Record Updates

• Last Update Posted (Estimate): September 5, 2014
• Last Update Submitted That Met QC Criteria: September 4, 2014
• Last Verified: September 1, 2014

More Information

Terms related to this study

• Keywords: Body Composition; Cognitive Function; Cardiovascular Risk
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Nutrition Disorders; Insulin Resistance; Hyperinsulinism; Avitaminosis; Deficiency Diseases; Malnutrition; Metabolic Syndrome; Vitamin D Deficiency; Physiological Effects of Drugs; Micronutrients; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Vitamin D; Cholecalciferol; Vitamins; Ergocalciferols
• Other Study ID Numbers: HP-00040570; P30AG028747 (U.S. NIH Grant/Contract)